Therapy Areas: Central Nervous System
Isotopia Molecular Imaging collaborates with Y-mAbs Therapeutics
6 November 2020 -

Isotopia Molecular Imaging, a company formed by a collaboration between The Metrontario Group and some of Israel's leading scientists in the field of radiopharmaceuticals, has started a partnership with Y-mAbs Therapeutics Inc, a late-stage clinical biopharmaceutical company, it was reported on Thursday.

The collaboration is aimed at the supply of the medical radioisotope no-carrier-added Lutetium-177 to support clinical development for 177Lu-DTPA-omburtamab intended for the treatment of B7-H3 positive Central Nervous System and Leptomeningeal Metastasis from tumours in adult patients.

Isotopia's Business Development manager, Keren Moshkoviz said, 'Isotopia, Like Y-mAbs aims to improve quality of life of cancer patients with Targeted Radionuclide Therapies. We are very pleased to establish this alliance making significant contribution to innovative and promising therapies for cancer patients worldwide. Isotopia is focusing on supporting clinical studies also for the next generation of radio isotope Tb161 that will be launched soon. We are confident that our growing development platform will make a big contribution to targeted therapies worldwide.'

Login
Username:

Password: